Athernal Bio officially launches with £3.5 million funding from Delin Ventures to develop targeted immunotherapies for high-risk clonal haematopoiesis.

Oct 01, 2025•5 days ago

Amount Raised

£3.5 Million

CambridgeBiotechnologyHealth Care

Investors

Delin Ventures

Description

Athernal Bio announced its launch with £3.5 million funding from founding investor Delin Ventures. This funding supports preclinical milestones as the company works towards clinical trials. Focused on immunotherapies for clonal haematopoiesis, it seeks to prevent blood cancers. Led by experienced founders, Athernal Bio aims to fill a gap in targeted treatments.

Company Information

Company

Athernal Bio

Location

Cambridge, England, United Kingdom

About

Athernal Bio is developing targeted immunotherapies to treat blood cancer precursor conditions before cancers become established. The company’s primary focus is high-risk clonal haematopoiesis (CH), a widespread cancer precursor condition which can lead to acute myeloid leukaemia and other haematological cancers. High-risk CH affects multiple groups, including patients with rare blood disorders, cancer survivors, and the ageing population. Athernal Bio’s initial programme is an immunotherapy for patients with inherited rare blood disorders, associated with the most aggressive and highly accelerated forms of CH. Athernal Bio has built a strong team, supported by renowned advisors across the US and Europe, to rapidly develop the first therapeutic options for early intervention in patients with high-risk CH, aiming to stop cancer before it starts.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns